EICHORPublic-registry site landscape for NCT03536559, “Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis”, a Relapsing Remitting Multiple Sclerosis study sponsored by Clene Nanomedicine. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03536559 (registry record) |
| Study title | Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis |
| Official title | A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis |
| Sponsor | Clene Nanomedicine |
| Condition(s) | Relapsing Remitting Multiple Sclerosis; Optic Neuropathy; Optic; Neuritis, With Demyelination |
| Phase | PHASE2 |
| Listed sites | 7 |
| Site countries | United States, Australia, Canada |
Patient-friendly overview of this study: eichor.com/study/NCT03536559.
Eichor generates a preliminary site-risk snapshot for NCT03536559 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Relapsing Remitting Multiple Sclerosis trials
More from Clene Nanomedicine
← Eichor home · All tracked trials · Relapsing Remitting Multiple Sclerosis studies · Weekly briefs
